Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth H Mayer

Showing results (941-950 of 997) with videos related to

Pageof 100
Sort By:
JAMA Network Open|February 4, 2022
Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2Alfonso C Hernandez-Romieu, Thomas W Carton, Sharon Saydah, et al.
AIDS (London, England)|November 17, 2023
Weight loss associated with semaglutide treatment among people with HIVLara Haidar, Heidi M Crane, Robin M Nance, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Annals of Epidemiology|December 12, 2018
Viral suppression among persons in HIV care in the United States during 2009-2013: sampling bias in Medical Monitoring Project surveillance estimatesHeather Bradley, Keri N Althoff, Kate Buchacz, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
MMWR. Morbidity and Mortality Weekly Report|April 7, 2022
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022Jason P Block, Tegan K Boehmer, Christopher B Forrest, et al.
AIDS Care|January 25, 2021
Drug and alcohol use among people living with HIV in care in the United States by geographic regionHeidi M Crane, Robin M Nance, Bridget M Whitney, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
The Journal of Nutrition|March 13, 2026
A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 TrialDavaasambuu Ganmaa, Kaitlyn A Cook, Polyna Khudyakov, et al.
Pageof 100

Showing results (941-950 of 997) with videos related to

Sort By:
Pageof 100
JAMA Network Open|February 4, 2022
Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2Alfonso C Hernandez-Romieu, Thomas W Carton, Sharon Saydah, et al.
AIDS (London, England)|November 17, 2023
Weight loss associated with semaglutide treatment among people with HIVLara Haidar, Heidi M Crane, Robin M Nance, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Annals of Epidemiology|December 12, 2018
Viral suppression among persons in HIV care in the United States during 2009-2013: sampling bias in Medical Monitoring Project surveillance estimatesHeather Bradley, Keri N Althoff, Kate Buchacz, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
MMWR. Morbidity and Mortality Weekly Report|April 7, 2022
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022Jason P Block, Tegan K Boehmer, Christopher B Forrest, et al.
AIDS Care|January 25, 2021
Drug and alcohol use among people living with HIV in care in the United States by geographic regionHeidi M Crane, Robin M Nance, Bridget M Whitney, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
The Journal of Nutrition|March 13, 2026
A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 TrialDavaasambuu Ganmaa, Kaitlyn A Cook, Polyna Khudyakov, et al.
Pageof 100